Review Article

A Review of Artificial Inspiration in Drug Delivery Systems

KIRAN B DHAMAK*, AKSHATA PAGAR, VINAYAK M GAWARE
Department of Quality Assurance, PRES's College of Pharmacy (For Women), Chincholi, Nashik, 422102, Maharashtra, India

A R T I C L E   D E T A I L S

A B S T R A C T

By making therapy more precise, effective, and individualized, artificial intelligence (AI) is revolutionizing medication delivery methods. AI helps with drug design, controlled release, dose optimization, and targeted administration through machine learning, deep learning, and natural language processing. We are able technology, biosensors and nanotechnology integration provide adaptive therapies and real-time monitoring, while patient-specific modelling improves personalized medicine. Autonomous drug delivery systems, digital twins, intelligent Nano carriers, and other future advancements are all possible using AI-driven platforms, despite issues with data quality, ethics, regulation, and cost. This change in perspective has the potential to transform pharmaceutical treatment and enhance therapeutic results. This study provides a comprehensive overview of scientific advancements over the last ten years with the goal of igniting interest in the incorporation of various forms of artificial intelligence in AM and MFs as crucial methods for improving the quality standards of customized medicinal applications and lowering variability potency throughout a pharmaceutical process.

INTRODUCTION

Drug delivery is the process of administering a medication to either humans or animals in order to produce a therapeutic effect [1]. Machine learning (ML) and artificial intelligence (AI) have the potential to revolutionize medication development and advance other R&D fields. Insights into disease-target relationships, drug candidate selection, protein structure predictions, molecular compound design, the identification of mechanisms for disease processes, and ongoing research on prognostic and predictive biomarkers are some of these important areas. In addition, we use a variety of input through AI-ML and its applications in biometric data analysis, wearables, personalized medicine, and clinical trial data analysis to achieve efficiency for better experimental outcomes during the pandemic era while adopting (Right way of Data collection method with Site monitoring), [2]. In addition to human capabilities, some crucial factors including dose customization, targeted drug delivery, continuous release, and intelligent control must be taken into account while designing an implanted drug delivery system [3].

AI's Part
Machine Literacy (ML) includes underpinning literacy, unsupervised literacy, and supervision

Deep literacy (DL) CNNs, RNNs, and neural networks

**Natural Language Processing (NLP)** For clinical trial analysis and literature mining [4]

Machine Learning (ML):
Supervised AI Learning: This is the most widely used method of learning, which involves matching each input data point with the corresponding output by training a model with labelled data or labelled ground truth [6]. For example: Image classification: the system is trained to identify objects within images using examples akin to labelling.

Unsupervised AI Learning: Researching possible algorithmic paths to organize and clean up chaotic inputs is helpful when creating better predictive models [7].

Author for Correspondence:
Email: kirandhamak21@gmail.com

Figure 1: AI Methods in Drug Delivery Systems [5]

As an example: Autoencoders, anomaly detection, association, and grouping are a few examples [8].

Reinforcement Learning: In reinforcement learning, the model determines how to complete a task without the use of pretrained data. Unlike training data, the model in reinforcement learning learns by its experience [9]. Based on something in the world, the algorithm begins to develop a policy that instructs the agent on how to behave [9]. The environment is impacted by every action, and the environment provides feedback that guides the learning process [10]. For example, self-driving cars receive a positive reward for navigating the streets successfully and receive a punishment for making mistakes [11].

Deep Learning (DL):
Neural Learning: An algorithm for computational machine learning is called an artificial neuron (ANN). The suppression padding of in inspirational biology. The artificial neural network (ANN) is composed of nodes, each of which is analogous to a cell in the human body. These nodes communicate with one another through connections, much like the axons and dendrites of nerves in the body. The connections between nodes in an ANN are given weights based on how well they can approximate the desired output, much like how synapses between neurons are strengthened when their neurons have correlated outputs in a biological

neural network (the Hebbian theory says that "nerves that fire together, wire together").
For example, recurrent neural networks (RNN), convolutional neural networks (CNN), and generative adversarial networks (GAN) [12].

AI Applications in Drug Delivery
- Target Drug Delivery
- Controlled Release System
- Drug Formulation Design

Target Drug Delivery: This project's use of the AI platform in TBDR makes it clear that it moved away from conventional empirical designs and toward a closed-looped, intelligent design framework. A live workflow is now possible thanks to this modification, where each stage is informed by data and continuously improved by iterative feedback [13].

Controlled Release System: AI has great potential in the field of drug release control. The dynamic biological environment is not always taken into account by empirical designs used in conventional controlled-release systems. Researchers can develop release profiles and precisely target a particular duration of action by teaching AI models to map out a drug's release under various physiological situations. By combining data from in vitro and in vivo trials, certain machine learning algorithms can calculate release kinetics and estimate the best time for drug release that produces the Topmost

remedial impact with the smallest possible side goods [15].

Figure 2: Targeted Drug Delivery System [14]

Drug Formulation Design: Molecular mechanics (MM) is a technique that approximates molecular motion using the rules of classical mechanics while avoiding the computing overhead required to build quantum mechanical techniques. MM is a strong method that has been used for ages to analyse the structures and interactions of ligands and proteins in order to optimize leads. This is achieved by the MM potential energy function, which is only the total of different kinds of molecular energies known as "force fields" [16].

Patient Specific Modelling in AI for *Personalised Medicine & DDS:* The goal of personalized medicine and drug delivery systems (DDS) is to provide individualized healthcare by taking into account the unique characteristics of each patient. At its core is AI-driven patient-specific modelling, which uses data and algorithms to forecast a patient's reaction to a condition, treatment, or medication formulation.

1. Patient-Specific Modelling:
The term "patient-specific modelling" describes the application of computer methods to generate a virtual portrait of a person's biological system according to their particular:
- The genetic profile
- The study of physiological
- State of the disease
- surroundings and lifestyle

2. AI Enhances These Models By Enabling:
- Predicting therapy response;
- Simulating drug transport and pharmacokinetics;
- Integrating data from many sources (genomics, imaging, EHRs)

3. AI in Personalised Medicine Using Patient-Specific Modeling Applications:
- Genomic modeling: AI finds actionable mutations (like BRCA in breast cancer) by analyzing whole-genome sequencing data.
- Predictive Models: Machine learning models predict how a disease will develop and how a treatment willwork.
- Digital Twins: AI builds a patient's "digital twin" to model various therapy scenarios *in silico*.

For instance, in oncology, deep learning algorithms have been taught to use tumor biomarkers to match patients with the most successful immunotherapies [17].

AI Contributions:
- Targeted DDS Design: Artificial intelligence models create liposomes or nanoparticles for customized drug delivery, such as tumor-targeted delivery.
- Dose Optimization: AI forecasts the best medication schedule and dosage based on a patient's disease state and metabolism.
- Controlled Release Modeling: This technique uses machine learning to predict how medications will release over time in organs or tissues unique to each patient.

Example:
- By using AI to estimate the pharmacokinetics of insulin delivery in diabetic patients, customized release based on glucose levels and meal timing was made possible [18].

Table 1: Patient Specific Modelling in AI for Personalised Medicine & DDS

Feature	Description	AI Role
Digital Twins	Simulate patient response to treatment *in silico*	Deep learning, physics-informed models
Real-time Feedback	Adjust therapy based on sensor data	Reinforcement learning, adaptive models
Pharmacogenomics	Link genes to drug metabolism	NLP & ML on genomic + clinical data

AI Combines Nanotechnology with Smart Materials in the Design of Nanocarriers:

1. AI-Driven Nanocarrier Design & Optimization

- *Optimizing Physical Parameters:* In order to anticipate the best nanocarrier designs for improved biodistribution, tumor penetration, and cellular uptake, AI/ML algorithms may evaluate complicated datasets by analyzing characteristics such as particle size, shape, surface charge, and functionalization. For example, based on therapeutic objectives, AI models assist in determining whether spherical or rodshaped nanoparticles perform better.

- *Tailored Surface Functionalization:* To improve targeting and lower immunogenicity, AI can recommend the ideal ligands or PEGylation density. In tumor microenvironments, it can forecast ligandreceptor interactions that are essential for targeted delivery (e.g., liver cancer).

- *Release Kinetics Modeling:* For controlled therapeutic release, especially in acidic tumors, artificial intelligence (AI) models mimic and optimize drug release profiles that are driven by pH, temperature, or other environmental causes [19].

2. Smart, Adaptive Systems & Real-Time Feedback

- *In Charge: AI-integrated Nanobots and Nano Carriers:* ML foreshadows real-time traceability, quick sensor response (adaptive), self-learning based on feedback, and self-directed system variable changes for improved delivery.

- *Monitoring Release and Efficacy:* By using biosensors or imaging combined with Nano carriers, which AI systems could analyse in real-time, drug-release parameters may be adjusted for the ideal dosage while minimizing side effects.

- *Nano-intelligent Devices Replicating the Exosomal Trafficking System:* AI collaborating with Nano carriers to guide tumour-targeting treatment and recycle the cargo after identifying exosomal molecular signatures [20].

3. Personalized and Accurate Nanomedicine

- *Customized Nano Carrier Design:* AI examines patient data from many comics, such as proteomics, genomes, and epigenetics, to determine the best kind of Nano carrier to target ligands and medication payloads for each individual.

- *In Terms of Mental Health:* AI-enabled nanomaterial's, therapeutic drug delivery from outside the tumour, review, support imaging, and diagnostic feedback (to visualize activation) are all examples of "see and treat" strategies.

- *Clinical Trial Advancement:* By using a Venn-like method to correlate nanocarrier properties to inmate biomarkers and clinical data in patient records, AI makes it possible to identify responders and combination regimens [21].

Figure 3: Artificial Intelligence for Personalized Nano medicine

4. Quicker Development of Surface Engineering and Smart Materials

• *Find New Materials Using AI*: By training machine learning models and generative model pipelines like GANs or VAEs to automate the setup via online synthesis robots, high-tech functional smart materials (such as stimuli-responsive, biocompatible, and mechanically strong) and nanomaterials can be discovered.

• *Reverse Design Strategies:* AI models can generate candidate structures with desired properties based on your initial set of properties, avoiding the trial-and-error process of other methods.

• *Functionalization of the Tuning Surface:* The AI accurately predicts and creates ligand shells for particular molecular or cell patterns [22].

Biosensors for Real-Time Drug Delivery Definition:

Analytical tools called biosensors assist in transforming a biological reaction into an electrical signal, which is then utilized for the real-time detection of compounds like pharmaceuticals.

Participation in Drug Surveillance:

• Assess the amount of drug present in bodily fluids, such as blood, perspiration, saliva, and ISF.

• Make pharmacokinetic monitoring possible in real time.

• To maintain therapeutic ratios, make sure that medications are exchanged quickly.

Biosensors for Therapeutic Drug Monitoring (TDM) in Real Time

Traditional TDM uses intermittent sampling, which only records the drug level profile at specific times. In contrast, biosensors provide dynamic and continuous monitoring of disease biomarkers for real-time drug level tracking, improving dosage safety and accuracy.

Drug-Specific Biosensor Applications:

• *Vancomycin:* With better control over the beginning of nephrotoxicity, a vancomycin-specific probe that offers quick and accurate quantification in rabbits using a fluorescence-based biosensor may take the role of HPLC or immunoassay techniques.

• *AUS Warfarin:* A portable, accurate, and easy-to-use point-of-care blood warfarin monitoring system.

• *Valproic Acid:* is a potentiometric biosensor that can measure human blood levels quickly (less than 10 seconds) and accurately, much like traditional clinical tools.

• *Chemotherapy Agent's Electrochemical Biosensors Have Been Developed by Researchers to Identify Rubicund and Antineutrino.* For doxorubicin, these biosensors have a 0.6 NM discovery limit and a high sensitivity.

• *The Real-Time Data on Tumour Tissue Pharmacokinetics:* provided by implantable microelectrode arrays is very different from blood-based measures. The drug-efficacy evaluations might be enhanced and biopsies could be replaced.

• *Wearable Biosensors:* Thanks to developments in wearable technology, it is now possible to continuously and non-invasively monitor drugs in interstitial fluid or sweat. This offers up-to-date information to improve dosage and support validated medications [23].

Important Data Sources for AI in Medication Administration
A. Platforms and Curated Datasets

• ***Therapeutics Data Commons (TDC):*** 66 AI-ready datasets on a platform for research and discovery tasks. It features tools for assessing models, leaderboards, and producing oracles. It is therefore a great tool for assessing machine learning on therapeutic issues [24].

a) Tools for ADMET Prediction

• Free AI tools that aid in predicting absorption, distribution, metabolism, excretion, and toxicity include **AdmetSAR 2.0, ADMETLab 2.0, FP ADMET**, Interpretable **ADMET, and HelixADMET.** These elements are essential for drug behavior modeling.

b) Networks for Toxicology

• As part of IMI, the eTOX effort gathers preclinical toxicological data to lessen the need for animal testing and enhance side effect forecasts using computer models. AI models that need toxicity profiles can benefit from this data.

c) Synthetic and Proprietary Datasets

• A synthetic dataset to improve drug–protein interaction prediction was recently released by **SandboxAQ** (a Google-backed company supported by Nvidia), which is a step forward for designing pathway-aware delivery systems.

d) Information about Molecular Structure

• DeepMind's AlphaFold 3 models binding and dynamics by predicting the structures and interactions of biomolecules, including possible therapeutic possibilities [25].

Practical, Ethical, and Regulatory Aspects
1. Regulatory Aspects
a. Respecting the Regulations for Medical Devices

- Medical equipment frequently include AI-integrated drug delivery systems like smart pumps and nanocarriers. They've to abide by rules similar as of o FDA (USA): AI/ML Action Plan (2021): Software as a Medical Device (SaMD) under 21 CFR Part 820.
- The European Medicines Device Regulation (EU MDR 2017/745) is often known as the EMA. o Pharmaceutical ICH Guidelines might potentially be relevant. ICH Q8, Q9, and Q10, for instance

b. Verification and Openness.

- Explainable AI, another name for AI models, must be transparent to regulatory bodies. Clear documentation of the following is part of this: Training data sources
- The architecture and validation of the model
- Performance metrics and risk analysis.

c. After-market Monitoring

- AI systems must be covered after deployment in order to avoid the drift of algorithms
- Safety-related concerns
- Performance disparities in the real world [26].

2. Ethics-Related Issues
a. Security and Privacy of Data

- AI model training case data must adhere to insulation laws.
- To protect medical records, HIPAA (USA) and GDPR (EU)
- Assuring data anonymization, safe storage, and limited access are all part of this.

b.Both Fairness and Bias

- AI systems that are trained on biased datasets may result in disparities in medicine delivery based on gender or race.
- Disproportionate health consequences

c.Knowledgeable Consent and Independence

- When AI is used in their treatment, such as for automated dosage adjustments, patients should be informed.
- When autonomous AI bots make decisions without human supervision, ethical concerns arise.

d. Being Responsible

- Uncertain accountability for AI-driven systems' malfunctions or damage [27].

3. Relevant Practical Aspects
a. Availability and Quality of Data

- Healthcare frequently lacks the big, high-quality, labeled datasets that AI models require.
- Although it is difficult, integration with electronic health records (EHRs) is crucial.

b. Including Clinical Workflows

- AI needs to be integrated with current systems, including medication delivery devices and medical software. It shouldn't interfere with patient care or add to professionals' workload.

c. Interoperability

- Standardized protocols, including HL7 and FHIR standards, are required to guarantee AI can function across various devices, manufacturers, and healthcare systems.

d. Infrastructure and Cost

- Exorbitant maintenance and development expenses, particularly for smaller healthcare providers.
- Technical know-how and support mechanisms, such cloud computing and safe data storage, are required. [28, 29].

AI's Future Prospects in Drug Delivery Systems
1. Customized Medication Administration

Future Trend: AI will enable patient-specific medication compositions and delivery schedules. This will depend on behavioral, physiological, and genetic information.

- AI Can dissect biomarkers, genomic data, and EHRs to ascertain:
  - The ideal dosage
  - The administrative route
  - The delivery time

- This will result in more accurate medication and fewer negative drug effects [30].

2. AI-Powered Intelligent Medication Delivery Systems

- Future Trend: AI will be combined with wearable technology, biosensors, and smart nanocarriers to build self-operating drug delivery systems.
- Drugs will be released instantly when systems identify changes in the body, such as inflammation and glucose levels.
- The application of AI to closed-loop and feedback loops.AI-driven insulin pumps that respond instantly to blood sugar levels are one example.

3. AI-Powered Drug Carrier Design

- Future Trend: AI will be utilized to create novel drug delivery systems with the best qualities, including hydrogels, liposomes, and nanoparticles.
- AI is able to forecast and simulate:
  - Efficiency of drug encapsulation
  - Biodegradability
  - Targeting ability
- Application of deep learning (DL) and machine learning (ML) to material discovery.

4. AI for Forecasting the Kinetics and Behavior of Drug Release

- Future Trend: AI models will predict how medications will be released from delivery devices under various physiological circumstances.
- Offers improved command over:
  - Release timing
  - Site-specific advertising
  - Cutting down on systemic exposure
- This reduces negative effects and enhances the effectiveness of treatment.

5. Integration with IoT and Digital Health

- Future Trend: Digital health ecosystems will include AI-powered medication delivery systems that interface with:
  - Wearables, such as smart watches Mobile phones
- Cloud-based systems for remote observation and assistance Advantages Benefits:
  - Remote dosage modifications
  - Analyzing data in real time
  - Increased patient compliance

6. Regulatory Science and Artificial Intelligence in Clinical Trials

- Future Trend: We'll keep using AI to speed up and improve clinical trials of drug delivery systems and obtain any regulatory approvals we still want.
- Forecast the results of trials
- Make the most of patient acquisition
- Use predictive analytics to expedite regulatory submissions.

CONCLUSION

Artificial intelligence has revolutionized medication delivery methods by providing precise, efficient, and customized solutions. Machine learning, deep learning, natural language processing, and improved data integration may be used to build targeted delivery locations, such as controlled release systems and personalized medicine formulations. When paired with nanotechnology, biosensors, and the Internet of Things, this will allow for real-time monitoring, dosage modification, and autonomous treatment platforms that seek to enhance therapeutic results and offer solutions for improved patient adherence. However, before AI can be applied in pharmaceutical delivery, challenges including cost, interoperability, data quality, ethical concerns, and regulatory compliance need to be resolved. This encourages the creation of future completely patient-specific AI-guided drug delivery systems with integrated in-silico Pharmaceutical therapy will be revolutionized by predictive analytics and intelligent materials, which provide a pipeline from drug discovery to clinical usage.

ACKNOWLEDGMENT

REFERENCES

[1] Adir, Omer, Maria Poley, Gal Chen, Sahar Froim, Nitzan Krinsky, Jeny Shklover, Janna ShainskyRoitman, Twan Lammers, and Avi Schroeder. 2020. "Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine." *Advanced Materials* 32(13).

[2] Alshawwa, Samar Zuhair, Abeer Ahmed Kassem, Ragwa Mohamed Farid, Shaimaa Khamis Mostafa, and Gihan Salah Labib. 2022. "Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future

Perspectives and Implementation of Artificial Intelligence." *Pharmaceutics* 14(4):883.

[3] Bae, Hayeon, Hyunsub Ji, Konstantin Konstantinov, Ronald Sluyter, Katsuhiko Ariga, Yong Ho Kim, and Jung Ho Kim. 2025. "Artificial Intelligence-Driven Nanoarchitectonics for Smart Targeted Drug Delivery." *Advanced Materials.*

[4] Bhange, Manjusha, and Darshan Telange. 2025. "Convergence of Nanotechnology and Artificial Intelligence in the Fight against Liver Cancer: A Comprehensive Review." *Discover Oncology* 16(1):77.

[5] Bhatt, Parag, and Ashutosh Muduli. 2023. "Artificial Intelligence in Learning and Development: A Systematic Literature Review." *European Journal of Training and Development* 47(7/8):677–94.

[6] Chandrakala, V., Valmiki Aruna, and Gangadhara Angajala. 2022. "Review on Metal Nanoparticles as Nanocarriers: Current Challenges and Perspectives in Drug Delivery Systems." *Emergent Materials* 5(6):1593–1615.

[7] David Oyekunle, David Boohene, Ugochukwu Okwudili Matthew, and David Preston. 2024. "Trust beyond Technology Algorithms: A Theoretical Exploration of Consumer Trust and Behavior in Technological Consumption and AI Projects." *Journal of Computer and Communications* 12(6).

[8] Dedeloudi, Aikaterini, Edward Weaver, and Dimitrios A. Lamprou. 2023. "Machine Learning in Additive Manufacturing & Microfluidics for Smarter and Safer Drug Delivery Systems." *International Journal of Pharmaceutics* 636.

[9] Dilshod Nematov, and Mirabbos Hojamberdiev. 2025. "Introduction to Machine Learning, Neural Networks, and Deep Learning." 1.

[10] Hemdan, Mohamed, Mohamed A. Ali, Ahmed S. Doghish, Sherif S. Abdel Mageed, Ibrahim M. Elazab, Magdy M. Khalil, Mostafa Mabrouk, Diganta B. Das, and Alaa S. Amin. 2024. "Innovations in Biosensor Technologies for Healthcare Diagnostics and Therapeutic Drug Monitoring: Applications, Recent Progress, and Future Research Challenges." *Sensors* 24(16):5143.

[11] Jena, Goutam Kumar, Ch Niranjan Patra, Sruti Jammula, Rabinarayan Rana, and Shibani Chand. 2024. "Artificial Intelligence and Machine Learning Implemented Drug Delivery Systems: A Paradigm Shift in the Pharmaceutical Industry." *Journal of Bio-X Research* 7.

[12] Jiang, Fei, Yong Jiang, Hui Zhi, Yi Dong, Hao Li, Sufeng Ma, Yilong Wang, Qiang Dong, Haipeng Shen, and Yongjun Wang. 2017. "Artificial Intelligence in Healthcare: Past, Present and Future." *Stroke and Vascular Neurology* 2(4):230–43.

[13] Kexin Huang, Tianfan Fu, Wenhao Gao, Yue Zhao, Yusuf Roohani, Jure Leskovec, Connor W Coley, Cao Xiao, Jimeng Sun, and Marinka Zitnik. 2021. "Therapeutics Data Commons: Machine Learning Datasets and Tasks for Drug Discovery and Development." *Cornell University* 1.

[14] Khan, Zaitoon, Nimra Khan, Mithra Geetha, Reyhanath Pilakka Veettil, Deepak Mahadev Kasote, Anwarul Hasan, and Kishor Kumar Sadasivuni. 2025. "Therapeutic Applications of Nanobots and Nanocarriers in Cancer Treatment." *Analytical Sciences* 41(8):1305–24.

[15] Mak, Kit-Kay, and Mallikarjuna Rao Pichika. 2019. "Artificial Intelligence in Drug Development: Present Status and Future Prospects." *Drug Discovery Today* 24(3):773–80.

[16] Manne, Ravi. 2021. "Machine Learning Techniques in Drug Discovery and Development." *International Journal of Applied Research* 7(4):21–28.

[17] Mirnezami, Reza, Jeremy Nicholson, and Ara Darzi. 2012. "Preparing for Precision Medicine." *New England Journal of Medicine* 366(6):489–91.

[18] Mittelstadt, Brent. 2019. "Principles Alone Cannot Guarantee Ethical AI." *Nature Machine Intelligence* 1(11):501–7.

[19] Naeem, Samreen, Aqib Ali, Sania Anam, and Muhammad Munawar Ahmed. 2023. "An Unsupervised Machine Learning Algorithms: Comprehensive Review." *International Journal of Computing and Digital Systems* 13(1):911–21.

[20] Nasteski, Vladimir. 2017. "An Overview of the Supervised Machine Learning Methods." *HORIZONS.B* 4:51–62.

[21] Rene Y Choi, Aaron S Coyner, Jayashree Kalpathy-Cramer, Michael F Chiang, and J Peter Campbell. 2020. "Introduction to Machine Learning, Neural Networks, and Deep Learning." *Translational Vision Science & Technology* 9(2):14–14.

[22] Sarker, Iqbal H. 2021. "Deep Learning: A Comprehensive Overview on Techniques,

Taxonomy, Applications and Research Directions." *SN Computer Science* 2(6):420.

[23] Sateesh Kumar Nallamala. 2022. "AI-Based Systems for Optimizing Drug Delivery Mechanisms: Leveraging Machine Learning to Improve Targeted Delivery, Controlled Release, and Bioavailability of Pharmaceuticals." *Essex Journal of AI Ethics and Responsible Innovation* 2:416–51.

[24] Shaikh, Zuber Peermohammed, and Satish Balkrishna Bhise. 2025. "Drug Design and Discovery Through Artificial Intelligence." Pp. 141–68.

[25] Tiwari, Gaurav, Ruchi Tiwari, SaurabhK Bannerjee, L. Bhati, S. Pandey, P. Pandey, and Birendra Sriwastawa. 2012. "Drug Delivery Systems: An Updated Review." *International Journal of Pharmaceutical Investigation* 2(1):2.

[26] Tran, Thi Tuyet Van, Hilal Tayara, and Kil To Chong. 2023. "Recent Studies of Artificial Intelligence on In Silico Drug Distribution Prediction." *International Journal of Molecular Sciences* 24(3):1815. doi:10.3390/ijms24031815.

[27] Uddin, Md. Jasim, Amol D. Gholap, Tahseen Khan, Amrin Yeasin Proma, Sinthia Masud, Yahya E. Choonara, S. Gowri, Thomas J. Webster, and Md. Faiyazuddin. 2024. "The Integration of Nanotechnology, Artificial Intelligence (AI), Machine Learning (ML) and 3D-Bioprinting Approaches for Personalized COVID-19 Treatment." *Journal of Biomedical Nanotechnology* 20(12):1759–90.

[28] Vora, Lalitkumar K., Amol D. Gholap, Keshava Jetha, Raghu Raj Singh Thakur, Hetvi K. Solanki, and Vivek P. Chavda. 2023. "Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design." *Pharmaceutics* 15(7):1916.

[29] Wu, Yuyuan, Lijing Ma, Xinyi Li, Jingpeng Yang, Xinyu Rao, Yiru Hu, Jingyi Xi, Lin Tao, Jianjun Wang, Lailing Du, Gongxing Chen, and Shuiping Liu. 2024. "The Role of Artificial Intelligence in Drug Screening, Drug Design, and Clinical Trials." *Frontiers in Pharmacology* 15. doi:10.3389/fphar.2024.1459954.

[30] Zhang, Yue, Mengqi Luo, Peng Wu, Song Wu, Tzong-Yi Lee, and Chen Bai. 2022. "Application of Computational Biology and Artificial Intelligence in Drug Design." *International Journal of Molecular Sciences* 23(21):13568.